Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Appian Corp (APPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Appian Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.56 (market cap $5.07B), while Appian Corp trades at $34.78 (market cap $2.54B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Appian Corp nearer its low. Which is the better fit depends on your goals.
| ACAD | APPN | |
|---|---|---|
Market Cap | $5.07B | $2.54B |
Sector | Health | Technology |
52-Week High | $29.41 | $45.64 |
52-Week Low | $20.06 | $18.72 |
Enterprise Value | $4.19B | $2.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
Appian (APPN) trades at $34.42, down 3.26% on the day, following recent earnings beats but amid broader software stock volatility. The stock shows a bullish technical trend with moving averages supporting upside, though oscillators indicate overbought conditions. Fundamentally, revenue growth remains strong with 2025 revenue at $726.94 million and a return to positive net income of $1.23 million, yet profitability metrics like ROE at -936.62% highlight ongoing challenges. Recent news highlights AI-driven partnerships and enterprise demand as key growth catalysts.
The outlook is mixed: analyst consensus is cautious with a hold-heavy rating (63.16% hold) and a $32.50 price target below the current price, signaling limited near-term upside. Risks include high debt levels, negative equity, and competitive pressures in low-code software. Investment appeal hinges on sustained AI adoption and margin improvement, but volatility and weak shareholder equity pose significant risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →
